MiNK Therapeutics, Inc. (INKT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INKT SEC filings page.
This page shows MiNK Therapeutics, Inc. (INKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MiNK remains a development-stage business: losses persist, operating cash outflow is narrowing, and financing still supports a liability-heavy balance sheet.
Operating cash outflow shrank from$15.8M in FY2023 to$5.9M in FY2025, while the latest net loss remained$12.5M ; this divergence means cash usage improved faster than reported earnings. The gap points to changes beyond operating profitability, so the smaller cash outflow alone does not establish a business-model turnaround.
FY2025's current ratio recovered to 1.1x from 0.7x in FY2024, indicating near-term obligations were more closely matched by current assets. But total liabilities of
Development spending remained substantial: R&D was
Financial Health Signals
MiNK Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MiNK Therapeutics, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
MiNK Therapeutics, Inc. reported a net loss of $12.5M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
MiNK Therapeutics, Inc. reported an operating loss of $12.6M against $110K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
MiNK Therapeutics, Inc.'s EBITDA was -$3.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 11.8%.
MiNK Therapeutics, Inc. reported -$3.1M in net income in Q2 2026. This represents an increase of 26.2% from the same quarter a year earlier. Against the prior quarter it is down 14.1%.
MiNK Therapeutics, Inc. earned -$0.62 per diluted share (EPS) in Q2 2026. This represents an increase of 41.5% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.
Not reported for Q2 2026.
Cash & Balance Sheet
MiNK Therapeutics, Inc. held $8.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
MiNK Therapeutics, Inc. invested $1.9M in research and development in Q2 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 56.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
INKT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.9M+2.6% | $1.2M-4.6% | N/A | $1.1M+111.4% | $1.8M0.0% | $1.3M-50.5% | N/A | $541K-84.2% |
| SG&A Expenses | $1.3M-28.1% | $1.7M+32.0% | N/A | $1.8M+58.8% | $1.8M+74.2% | $1.3M-0.7% | N/A | $1.2M-35.2% |
| Operating Income | -$3.2M+20.6% | -$2.9M-6.7% | N/A | -$3.2M-68.9% | -$4.1M-32.0% | -$2.7M+29.5% | N/A | -$1.9M+63.9% |
| EBITDA | -$3.2M+20.6% | -$2.8M-7.4% | N/A | -$3.1M-72.3% | -$4.0M-32.3% | -$2.6M+29.8% | N/A | -$1.8M+64.8% |
| Interest Expense | -$2K+92.6% | -$4K+86.2% | N/A | -$25K+10.7% | -$27K-3.8% | -$29K-190.0% | N/A | -$28K-126.1% |
| Net Income | -$3.1M+26.2% | -$2.7M+0.9% | N/A | -$2.9M-59.8% | -$4.2M-56.8% | -$2.8M+27.4% | N/A | -$1.8M+64.7% |
| EPS (Basic) | -$0.62+41.5% | -$0.57+18.6% | -$0.54+79.5% | -$0.65-41.3% | -$1.06-45.2% | -$0.70+36.4% | -$2.64+56.3% | -$0.46-206.7% |
| EPS (Diluted) | -$0.62+41.5% | -$0.57+18.6% | -$0.54+79.5% | -$0.65 | -$1.06 | -$0.70 | -$2.64 | -$0.46 |
| Diluted Shares (Avg) | 5M+26.2% | 5M+21.0% | N/A | 4M | 4M | 4M | N/A | 4M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
INKT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.6M+287.0% | $10.4M+143.2% | $14.2M+148.9% | $15.0M+102.9% | $2.5M-75.9% | $4.3M-38.1% | $5.7M+25.7% | $7.4M-1.2% |
| Current Assets | $9.3M+362.2% | $10.0M+180.0% | $13.8M+177.6% | $14.5M+121.0% | $2.0M-78.8% | $3.6M-40.3% | $5.0M+38.6% | $6.6M+1.6% |
| Cash & Equivalents | $8.8M+423.6% | $9.5M+194.5% | $13.4M+191.9% | $9.5M+50.1% | $1.7M-81.9% | $3.2M-44.4% | $4.6M+35.9% | $6.3M-1.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $23.6M-14.6% | $23.1M-11.5% | $28.5M+12.5% | $28.5M+14.2% | $27.7M+2.9% | $26.1M-4.2% | $25.3M+11.9% | $24.9M+18.5% |
| Current Liabilities | $7.6M-42.5% | $7.3M-39.9% | $13.0M+87.2% | $13.4M+81.6% | $13.2M+29.7% | $12.1M+9.1% | $7.0M-39.0% | $7.4M-28.8% |
| Non-Current Liabilities | $16.1M+10.8% | $15.8M+13.2% | $15.4M-15.9% | $15.0M-14.2% | $14.5M-13.4% | $13.9M-13.3% | $18.3M+63.7% | $17.5M+64.6% |
| Total Equity | -$14.0M+44.3% | -$12.7M+41.8% | -$14.2M+27.4% | -$13.5M+23.0% | -$25.2M-52.0% | -$21.8M-7.4% | -$19.6M-8.5% | -$17.6M-29.3% |
| Retained Earnings | -$162.5M-7.5% | -$159.4M-8.5% | -$156.7M-8.7% | -$154.1M-8.7% | -$151.2M-8.1% | -$146.9M-7.1% | -$144.2M-8.1% | -$141.7M-10.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
INKT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M-32.7% | -$1.7M-29.2% | -$2.1M-20.0% | -$941K+68.6% | -$1.6M+31.5% | -$1.3M+47.3% | -$1.7M+43.1% | -$3.0M+28.8% |
| Depreciation & Amortization | $36K-26.0% | $36K-29.0% | $39K-28.4% | $44K-30.3% | $49K+8.1% | $51K-5.7% | $54K+0.6% | $63K+17.2% |
| Stock-Based Compensation | $422K-53.0% | $630K+6.6% | N/A | $621K-29.7% | $897K+6.3% | $591K-0.2% | N/A | $883K-6.0% |
| Financing Cash Flow | $1.4M+252891.5% | -$2.1M-364827.4% | $1.2M+39170200.0% | $13.5M+198954.8% | $540-100.0% | $576-100.0% | -$3-50.0% | $7K+130.5% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
INKT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$14.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. INKT | FY2025 | N/A | -$12.5M | N/A | $63.5M | — |
| Adicet Bio, Inc. ACET | FY2025 | N/A | -$116.8M | N/A | $60.8M | — |
| Werewolf Therapeutics, Inc. HOWL | FY2025 | N/A | -$60.8M | N/A | $45.1M | — |
| Artiva Biotherapeutics, Inc. ARTV | FY2025 | $0 | -$83.9M | N/A | $333.9M | — |
| ALX Oncology Holdings Inc. ALXO | FY2025 | N/A | -$101.7M | N/A | $168.7M | — |
| Prelude Therapeutics Incorporated PRLD | FY2025 | $12.1M | -$99.5M | N/A | $292.9M | 70/100 |
Where MiNK Therapeutics, Inc. Ranks
Frequently Asked Questions
Is MiNK Therapeutics, Inc. profitable?
No, MiNK Therapeutics, Inc. (INKT) reported a net income of -$12.5M in fiscal year 2025.
What is MiNK Therapeutics, Inc.'s EBITDA?
MiNK Therapeutics, Inc. (INKT) had EBITDA of -$12.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is MiNK Therapeutics, Inc.'s operating cash flow?
MiNK Therapeutics, Inc. (INKT) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are MiNK Therapeutics, Inc.'s total assets?
MiNK Therapeutics, Inc. (INKT) had $14.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does MiNK Therapeutics, Inc. spend on research and development?
MiNK Therapeutics, Inc. (INKT) invested $5.8M in research and development during fiscal year 2025.
What is MiNK Therapeutics, Inc.'s current ratio?
MiNK Therapeutics, Inc. (INKT) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.
What is MiNK Therapeutics, Inc.'s return on assets (ROA)?
MiNK Therapeutics, Inc. (INKT) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is MiNK Therapeutics, Inc.'s P/E ratio?
MiNK Therapeutics, Inc. (INKT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $63.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MiNK Therapeutics, Inc.'s price-to-sales ratio?
MiNK Therapeutics, Inc. (INKT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $63.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does MiNK Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, MiNK Therapeutics, Inc. (INKT) held $13.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is MiNK Therapeutics, Inc.'s debt-to-equity ratio negative or not reported?
MiNK Therapeutics, Inc. (INKT) has negative shareholder equity of -$14.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is MiNK Therapeutics, Inc.'s Piotroski F-Score?
MiNK Therapeutics, Inc. (INKT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MiNK Therapeutics, Inc.'s earnings high quality?
MiNK Therapeutics, Inc. (INKT) reported a net loss of $12.5M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can MiNK Therapeutics, Inc. cover its interest payments?
MiNK Therapeutics, Inc. (INKT) reported an operating loss of $12.6M against $110K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.